Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Your cardiologist or primary care physician can connect you to our colleagues in endocrinology, bariatric medicine, and other specialties
Human medicines in 2025 EMA (used as proxy for EMA EPAR database confirming no retatrutide authorisation)
Semaglutide (Ozempic, Wegovy): GLP-1 receptor agonist 31-amino acid peptide Position 2: Aib substitution Position 20: Lys acylated with a C18 fatty diacid via a Glu-(AEEA-AEEA) linker Position 28: Arg substitution Tirzepatide (Mounjaro, Zepbound): Dual GIP/GLP-1 receptor agonist 39-amino acid peptide: Position 2 and 13: Aib substitution Position 20: Lys acylated with a C20 fatty diacid via a Glu-(AEEA-AEEA) linker Position 30-39: Amino acid sequence from exenatide Retatrutide: Triple GLP-1/GIP/GCG receptor agonist 39-amino acid peptide: Position 2 and 20: Aib substitution Position 13: Leucine modified with an -methyl group (2-Methylleucine) Position 17: Lys acylated with a C20 fatty diacid via a Glu-(AEEA) linker Position 30-39: Amino acid sequence from exenatide Semaglutide and Tirzepatide are widely available and well-studied, while Retatrutide's long-term effectiveness and safety profile are still being investigated in clinical trials
Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: a prospective cohort study
J Biol Chem 271 : 1930419309 Kato H, Faria TN, Stannard B, Roberts Jr CT, LeRoith D (1993) Role of tyrosine kinase activity in signal transduction by the insulin-like growth factor-I (IGF-I) receptor
US$ 25.88
US$ 28.57
US$ 20.04
